VRDN — Viridian Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.10bn
- $464.23m
- $0.30m
Annual income statement for Viridian Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.05 | 2.96 | 1.77 | 0.314 | 0.302 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 111 | 82.7 | 136 | 255 | 299 |
| Operating Profit | -110 | -79.7 | -134 | -254 | -299 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -111 | -79.4 | -130 | -238 | -270 |
| Net Income After Taxes | -111 | -79.4 | -130 | -238 | -270 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -111 | -79.4 | -130 | -238 | -270 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -111 | -79.4 | -130 | -238 | -270 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -11.4 | -6.66 | -4.05 | -5.31 | -3.98 |